Page 380 - Read Online

Page 10 of 10 Yang et al. Plast Aesthet Res 2020;7:34 I http://dx.doi.org/10.20517/2347-9264.2020.24

41. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle 2005;4:256-8.
42. Cramer T, Johnson RS. A novel role for the hypoxia inducible transcription factor HIF-1alpha: critical regulation of inflammatory cell
function. Cell Cycle 2003;2:192-3.
43. Okuno R, Ito Y, Eid N, Otsuki Y, Kondo Y, et al. Upregulation of autophagy and glycolysis markers in keloid hypoxic-zone fibroblasts:
morphological characteristics and implications. Histol Histopathol 2018;33:1075-87.
44. Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci
2018;19:711.
45. Jiao H, Fan J, Cai J, Pan B, Yan L, et al. Analysis of characteristics similar to autoimmune disease in keloid patients. Aesthetic Plast Surg
2015;39:818-25.
46. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and
emerging treatment strategies. Mol Med 2011;17:113-25.
47. Tredget EE, Nedelec B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy.
Surg Clin North Am 1997;77:701-30.
48. Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 2009;23:178-84.
49. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci 2017;18:606.
50. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, et al. Chronic stress and age-related increases in the
proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A 2003;100:9090-5.
51. Graham JE, Robles TF, Kiecolt-Glaser JK, Malarkey WB, Bissell MG, et al. Hostility and pain are related to inflammation in older adults.
Brain Behav Immun 2006;20:389-400.
52. Webster Marketon JI, Glaser R. Stress hormones and immune function. Cell Immunol 2008;252:16-26.
53. Liu W, Wang DR, Cao YL. TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. Curr Gene
Ther 2004;4:123-36.
54. Lee CH, Hong CH, Chen YT, Chen YC, Shen MR. TGF-beta1 increases cell rigidity by enhancing expression of smooth muscle actin:
keloid-derived fibroblasts as a model for cellular mechanics. J Dermatol Sci 2012;67:173-80.
55. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998;4:19-24.
56. Ishihara H, Yoshimoto H, Fujioka M, Murakami R, Hirano A, et al. Keloid fibroblasts resist ceramide-induced apoptosis by
overexpression of insulin-like growth factor I receptor. J Invest Dermatol 2000;115:1065-71.
57. Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J Am Coll Surg 2008;206:731-41.
58. Ladak A, Tredget EE. Pathophysiology and management of the burn scar. Clin Plast Surg 2009;36:661-74.
59. Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann N Y Acad
Sci 2006;1069:62-76.
60. van den Broek LJ, van der Veer WM, de Jong EH, Gibbs S, Niessen FB. Suppressed inflammatory gene expression during human
hypertrophic scar compared to normotrophic scar formation. Exp Dermatol 2015;24:623-9.
61. Namazi MR, Fallahzadeh MK, Schwartz RA. Strategies for prevention of scars: what can we learn from fetal skin? Int J Dermatol
2011;50:85-93.
62. Liechty KW, Kim HB, Adzick NS, Crombleholme TM. Fetal wound repair results in scar formation in interleukin-10-deficient mice in a
syngeneic murine model of scarless fetal wound repair. J Pediatr Surg 2000;35:866-73.
63. Glaser R, Kennedy S, Lafuse WP, Bonneau RH, Speicher C, et al. Psychological stress-induced modulation of interleukin 2 receptor gene
expression and interleukin 2 production in peripheral blood leukocytes. Arch Gen Psychiatry 1990;47:707-12.
64. Glaser R, MacCallum RC, Laskowski BF, Malarkey WB, Sheridan JF, et al. Evidence for a shift in the Th-1 to Th-2 cytokine response
associated with chronic stress and aging. J Gerontol A Biol Sci Med Sci 2001;56:M477-82.
65. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol 2004;25:677-86.
66. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 2014;5:514.
67. Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun 2014;6:716-26.
68. Jin Q, Gui L, Niu F, Yu B, Lauda N, et al. Macrophages in keloid are potent at promoting the differentiation and function of regulatory T
cells. Exp Cell Res 2018;362:472-6.
69. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol 2012;3:51.
70. Dey A, Hankey Giblin PA. Insights into macrophage heterogeneity and cytokine-induced neuroinflammation in major depressive disorder.
Pharmaceuticals (Basel) 2018;11:64.
71. Chen X, Thibeault SL. Role of tumor necrosis factor-alpha in wound repair in human vocal fold fibroblasts. Laryngoscope
2010;120:1819-25.
72. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis
factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015;49:206-15.
73. Kohler CA, Freitas TH, Stubbs B, Maes M, Solmi M, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant
drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol 2018;55:4195-206.